Revenue: The sum of all revenue fields included for a company's operating activities.
Revance Therapeutics, Inc. (RVNC) had Revenue of $69.80M for the most recently reported fiscal quarter, ending 2023-12-31.
| Income Statement Financials | |
|
Revenue |
$69.80M |
$-55.70M |
|
$17.47M |
|
$52.33M |
|
$123.75M |
|
$-53.95M |
|
$-1.75M |
|
$-55.70M |
|
$-55.70M |
|
$-55.70M |
|
$-55.70M |
|
$-55.70M |
|
$-55.70M |
|
$-53.95M |
|
$-53.08M |
|
84.60M |
|
84.60M |
|
$-0.66 |
|
$-0.66 |
|
| Balance Sheet Financials | |
$338.87M |
|
$17.23M |
|
$139.59M |
|
$478.45M |
|
$89.22M |
|
$426.60M |
|
$540.83M |
|
$630.06M |
|
$-151.60M |
|
$-161.41M |
|
$-151.60M |
|
87.96M |
|
| Cash Flow Statement Financials | |
$-216.57M |
|
$109.74M |
|
$136.57M |
|
$115.02M |
|
$144.75M |
|
$29.73M |
|
$47.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.80 |
|
-- |
|
-- |
|
1.55 |
|
-2.85 |
|
74.97% |
|
-77.30% |
|
-77.30% |
|
-- |
|
-79.80% |
|
-79.80% |
|
$-223.46M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.38 |
|
2.52 |
|
35.69 |
|
36.74% |
|
34.51% |
|
-11.64% |
|
-20.25% |
|
$-1.72 |
|
$-2.64 |
|
$-2.56 |
|